Jelinek J - Search Results

1

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.

Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Oki Y, et al. Among authors: jelinek j. Blood. 2008 Feb 15;111(4):2382-4. doi: 10.1182/blood-2007-07-103960. Epub 2007 Nov 30. Blood. 2008. PMID: 18055864 Free PMC article. Clinical Trial.

2

Mutations in the VHL gene in sporadic apparently congenital polycythemia.

Pastore YD, Jelinek J, Ang S, Guan Y, Liu E, Jedlickova K, Krishnamurti L, Prchal JT. Pastore YD, et al. Among authors: jelinek j. Blood. 2003 Feb 15;101(4):1591-5. doi: 10.1182/blood-2002-06-1843. Epub 2002 Oct 10. Blood. 2003. PMID: 12393546 Free article.

3

Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin.

Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Liu E, et al. Among authors: jelinek j. Blood. 2003 Apr 15;101(8):3294-301. doi: 10.1182/blood-2002-07-2287. Epub 2002 Dec 19. Blood. 2003. PMID: 12515724 Free article.

4

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.

Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Issa JP, et al. Among authors: jelinek j. J Clin Oncol. 2005 Jun 10;23(17):3948-56. doi: 10.1200/JCO.2005.11.981. Epub 2005 May 9. J Clin Oncol. 2005. PMID: 15883410 Clinical Trial.

5

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.

Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. Jelinek J, et al. Blood. 2005 Nov 15;106(10):3370-3. doi: 10.1182/blood-2005-05-1800. Epub 2005 Jul 21. Blood. 2005. PMID: 16037387 Free PMC article.

6

Silencing of bidirectional promoters by DNA methylation in tumorigenesis.

Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP. Shu J, et al. Among authors: jelinek j. Cancer Res. 2006 May 15;66(10):5077-84. doi: 10.1158/0008-5472.CAN-05-2629. Cancer Res. 2006. PMID: 16707430

7

Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.

Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Oki Y, et al. Among authors: jelinek j. Haematologica. 2006 Aug;91(8):1147-8. Epub 2006 Jul 25. Haematologica. 2006. PMID: 16870548

8

Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.

Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, Dressman HK, Jelinek J, Issa JP. Gollob JA, et al. Among authors: jelinek j. Clin Cancer Res. 2006 Aug 1;12(15):4619-27. doi: 10.1158/1078-0432.CCR-06-0883. Clin Cancer Res. 2006. PMID: 16899610 Clinical Trial.

9

Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence.

Kim J, Kim JY, Song KS, Lee YH, Seo JS, Jelinek J, Goldschmidt-Clermont PJ, Issa JP. Kim J, et al. Among authors: jelinek j. Biochim Biophys Acta. 2007 Jan;1772(1):72-80. doi: 10.1016/j.bbadis.2006.10.004. Epub 2006 Oct 12. Biochim Biophys Acta. 2007. PMID: 17110088 Free article.

10

RPS19 and JAK2 genes are not silenced by DNA methylation in diamond blackfan anemia.

Jelinek J, Issa JP, He R, Cmejla R, Cmejlova J, Pospisilova D. Jelinek J, et al. J Pediatr Hematol Oncol. 2007 Mar;29(3):207-8. doi: 10.1097/MPH.0b013e318033a75a. J Pediatr Hematol Oncol. 2007. PMID: 17356406 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

532 results

Search Page

Filters